Novel Agents for the Treatment of Anemia of Chronic Kidney Disease
Epoetin or darbepoetin alfa have suggested dosing regimens of 2-3 times/week to once every 1-2 weeks, but methoxy polyethylene glycol-epoetin beta, a novel ESA currently under development for the treatment of anemia in patients with CKD, may allow for extension of the dosing interval while providing maintenance hemoglobin levels. Methoxy polyethylene glycol-epoetin beta is chemically synthesized and is different from erythropoietin by switching the bonds between the amino groups and methoxy polyethylene glycol-succinimidyl butanoic acid. This novel agent has been designed to have reduced receptor affinity and decreased receptor mediated elimination. In clinical trials, methoxy polyethylene glycol-epoetin beta has a serum half-life of 133 ± 9.83 hours (IV) and 137 ± 21.9 hours (SC) and its pharmacokinetics support a different interaction with the epoetin receptor. Because of this long half-life, dosing at extended intervals (every 4 weeks, or once a month) may be possible. In contrast, the in vivo serum half-life of epoetin beta is approximately 8 hours. What follows are summarizations of key data that were presented on methoxy polyethylene glycol-epoetin beta and other issues surrounding anemia management in patients with CKD.
Medscape Nephrology © 2007 Medscape
Cite this: Highlights of the Annual Dialysis Conference: Chronic Kidney Disease Related-Anemia - Medscape - Apr 02, 2007.